Furlani, Lara
Furlani, Lara
DIPARTIMENTO DI MEDICINA
Mostra
records
Risultati 1 - 2 di 2 (tempo di esecuzione: 0.003 secondi).
Modified HyperCVAD and rituximab for the treatment of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
2013-01-01 Bonifacio, Massimiliano; Furlani, Lara; Zamo', Alberto; Corradi, Gabriele; Chilosi, Marco; Todeschini, Giuseppe; Pizzolo, G; Ambrosetti, Achille
Short-term, intensive chemotherapy regimen is equally effective in Burkitt lymphoma (BL) and in the novel WHO 2008 entity “B-cell lymphoma intermediate between DLBCL and BL".
2011-01-01 Bonifacio, Massimiliano; Furlani, Lara; Zamo', Alberto; Corradi, Gabriele; Moretta, Francesca; Mosna, F; Carli, G; Chilosi, Marco; Todeschini, Giuseppe; Ambrosetti, Achille; Pizzolo, G.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Modified HyperCVAD and rituximab for the treatment of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. | 1-gen-2013 | Bonifacio, Massimiliano; Furlani, Lara; Zamo', Alberto; Corradi, Gabriele; Chilosi, Marco; Todeschini, Giuseppe; Pizzolo, G; Ambrosetti, Achille | |
| Short-term, intensive chemotherapy regimen is equally effective in Burkitt lymphoma (BL) and in the novel WHO 2008 entity “B-cell lymphoma intermediate between DLBCL and BL". | 1-gen-2011 | Bonifacio, Massimiliano; Furlani, Lara; Zamo', Alberto; Corradi, Gabriele; Moretta, Francesca; Mosna, F; Carli, G; Chilosi, Marco; Todeschini, Giuseppe; Ambrosetti, Achille; Pizzolo, G. |